Subcommittee authorizes $21.25 million in opioid abatement grants to clear backlog and fund anticipated awards
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
The Appropriations Subcommittee approved $21,253,659 in opioid abatement grants administered through the Attorney General's office to address prior‑year applicant backlogs and anticipated grants; transcript notes Purdue Pharma settlement funds are dedicated to OSU Tulsa and excluded from this authorization.
The Appropriations Subcommittee on Public Safety and Judiciary approved authorization for $21,253,659 in opioid abatement grants to be administered through the Attorney General's office.
Committee discussion identified the opioid fund as settlement money from opioid manufacturers other than Purdue Pharma; the transcript notes Purdue Pharma's settlement proceeds are specifically dedicated to the OSU treatment facility in Tulsa and therefore are not part of this appropriation. Committee members said last year the program received nearly $10,000,000 more in applications than available funds; the appropriation is intended to fulfill prior‑year applications and anticipated awards for the coming year.
A motion to approve the grants, as stated in the transcript, was made and seconded; the subcommittee approved the motion by voice vote.
The appropriation authorizes the Attorney General's office to distribute the named funds to eligible applicants under the state's opioid abatement grant procedures; the transcript does not list individual grant recipients or a distribution schedule.